Clin Mol Hepatol > Accepted Articles
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage
Teng-Yu Lee1,2, Pei-Chien Tsai3, Shou-Wu Lee1,2,4, Ming- Lung Yu3,5
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
2School of Medicine, Chung Shan Medical University, Taichung, Taiwan
3Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
4Department of Post-Baccalaureate Medicine, College of Medicine, Chung Hsing University, Taichung, Taiwan
5Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan
Correspondence :  Ming- Lung Yu ,
Email: fish6069@gmail.com
Received: February 28, 2025   Accepted: March 1, 2025
KeyWords: chronic hepatitis C; antivirals; sustained virological response; liver cancer; survival

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1064
TOTAL : 2632063
Close layer